Minakem Generic APIs Minakem Generic APIs

X

Find the latest Drugs in Development and Pipeline Prospector News of Alkido Pharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Alkido Pharma
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
One Rockefeller Plaza 11th Floor New York, NY 10020
Telephone
Telephone
(703) 992-9325

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.


Lead Product(s): Psilocybine

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 07, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

AIkido Pharma has executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.


Lead Product(s): Psilocybine

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 06, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Company confirmed this week the successful synthesis of a critical intermediate compound for DHA-dFdC. Purification and isolation of this key intermediate were also completed and verified.


Lead Product(s): DHA-dFdC

Therapeutic Area: Oncology Product Name: DHA-dFdC

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 28, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

KPC34 was active against all AML cell lines tested with IC50s in the nanomolar range. Enforced expression of PLC increased response to KPC34 in vivo.


Lead Product(s): KPC34

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY